Compile Data Set for Download or QSAR
maximum 50k data
Found 41 Enz. Inhib. hit(s) with all data for entry = 995
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302048(US9598407, Compound 4)
Affinity DataIC50:  802nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302046(US9598407, Compound 2)
Affinity DataIC50:  821nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302056(US9598407, Compound 12)
Affinity DataIC50:  825nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302049(US9598407, Compound 5)
Affinity DataIC50:  927nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302053(US9598407, Compound 9)
Affinity DataIC50:  973nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302077(US9598407, Compound 34)
Affinity DataIC50:  1.14E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302051(US9598407, Compound 7)
Affinity DataIC50:  1.14E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302078(US9598407, Compound 35)
Affinity DataIC50:  1.27E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302080(US9598407, Compound 37)
Affinity DataIC50:  1.31E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302052(US9598407, Compound 8)
Affinity DataIC50:  1.31E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302057(US9598407, Compound 13)
Affinity DataIC50:  1.35E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302054(US9598407, Compound 10)
Affinity DataIC50:  1.37E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302047(US9598407, Compound 3)
Affinity DataIC50:  1.43E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302060(US9598407, Compound 16)
Affinity DataIC50:  1.47E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302071(US9598407, Compound 27)
Affinity DataIC50:  1.52E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302079(US9598407, Compound 36)
Affinity DataIC50:  1.58E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302075(US9598407, Compound 31)
Affinity DataIC50:  1.82E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302062(US9598407, Compound 18)
Affinity DataIC50:  1.85E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302055(US9598407, Compound 11)
Affinity DataIC50:  1.94E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302064(US9598407, Compound 20)
Affinity DataIC50:  1.99E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302065(US9598407, Compound 21)
Affinity DataIC50:  2.05E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302067(US9598407, Compound 23)
Affinity DataIC50:  2.18E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302066(US9598407, Compound 22)
Affinity DataIC50:  2.38E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302073(US9598407, Compound 29)
Affinity DataIC50:  2.46E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302072(US9598407, Compound 28)
Affinity DataIC50:  2.46E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302063(US9598407, Compound 19)
Affinity DataIC50:  2.62E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302058(US9598407, Compound 14)
Affinity DataIC50:  2.62E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302074(US9598407, Compound 30)
Affinity DataIC50:  3.16E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302083(US9598407, Compound 40)
Affinity DataIC50:  3.90E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302076(US9598407, Compound 32)
Affinity DataIC50:  3.97E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302069(US9598407, Compound 25)
Affinity DataIC50:  4.08E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302050(US9598407, Compound 6)
Affinity DataIC50:  4.46E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302061(US9598407, Compound 17)
Affinity DataIC50:  4.78E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302082(US9598407, Compound 39)
Affinity DataIC50:  6.61E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302084(US9598407, Compound 41)
Affinity DataIC50:  7.94E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302045(US9598407, Compound 1)
Affinity DataIC50:  9.32E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM133659(US8846711, 3 | US9051321, 3 | US9598407, Compound ...)
Affinity DataIC50:  9.56E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302059(US9598407, Compound 15)
Affinity DataIC50:  1.26E+4nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302068(US9598407, Compound 24)
Affinity DataIC50:  1.90E+4nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302081(US9598407, Compound 38)
Affinity DataIC50: >1.99E+4nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland

US Patent
LigandPNGBDBM302085(US9598407, Compound 42)
Affinity DataIC50:  2.23E+4nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent